Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 11/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 10/20 | 1.00 |
| ▸ | RORA | P35398 | 4/20 | 1.00 |
| ▸ | RORB | Q92753 | 4/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16063605 | 0.92 | RORC (0.86) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL6032023 | 0.88 | NR1I2 (0.79) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL3388210 | 0.87 | NR1I2 (0.78) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL12334077 | 0.87 | RORC (0.81) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL13651537 | 0.87 | NR1I2 (1.00) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL14732110 | 0.86 | RORC (1.00) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL14732184 | 0.85 | RORC (0.77) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL16731518 | 0.85 | RORC (0.81) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL7022970 | 0.83 | NR1H2 (0.71) | RORCNR1I2NR1H2RORARORB | |
| SCHEMBL7016049 | 0.82 | RORC (0.76) | RORCNR1I2NR1H2RORARORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1046 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070910-A | Preparation and application of nanoparticle for enhancing macrophage cytoburying function | 四川大学 | 2026-05-22 | — | — | CN | claimed |
| CN-122055154-A | Combination therapy | 澳大利亚悉尼大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4709383-A1 | INVERSE AGONISTS OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 Canada Inc. (CA) | 2026-03-18 | — | — | EP | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-20250305010-A1 | LIPID COMPOSITIONS AND METHODS OF PRODUCING SAME | WILK TECHNOLOGIES INTERNATIONAL LTD. (IL) | 2025-10-02 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | claimed |
| WO-2025081338-A1 | MODULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR FOR TREATMENT OF INFECTIONS | WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-24 | — | — | WO | claimed |
| WO-2025054665-A1 | COMBINATION THERAPY | THE UNIVERSITY OF SYDNEY (AU) | 2025-03-20 | — | — | WO | claimed |
| EP-4522724-A1 | LIPID COMPOSITIONS AND METHODS OF PRODUCING SAME | Wilk Technologies International Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| WO-2008036238-A2 | USE OF LXR MODULATORS FOR THE PREVENTION AND TREATMENT OF SKIN AGING | WYETH (US) | 2008-03-27 | — | — | WO | claimed |
| WO-2008036239-A2 | USE OF LXR AGONISTS FOR THE TREATMENT OF OSTEOARTHRITIS | WYETH (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080070883-A1 | Use of LXR modulators for the prevention and treatment of skin aging | WYETH (US) | 2008-03-20 | — | — | US | claimed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | claimed |
| EP-1758651-A2 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | Galapagos N.V. (BE) | 2007-03-07 | — | — | EP | claimed |
| WO-2006000577-A9 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | GALAPAGOS GENOMICS NV (BE) | 2006-04-20 | — | — | WO | claimed |
| US-20060020036-A1 | Methods and compositions to promote bone homestasis | GALAPAGOS N.V. (BE) | 2006-01-26 | — | — | US | claimed |
| WO-2006000577-A2 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | GALAPAGOS N.V. (BE) | 2006-01-05 | — | — | WO | claimed |
| US-6924311-B2 | Methods for affecting various diseases utilizing LXR compounds | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-08-02 | — | — | US | claimed |
| US-20040018560-A1 | Crystallized LXR polypeptide in complex with a ligand and screening methods employing same | SMITHKLINE BEECHAM CORPORATION | 2004-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070883-A1 | Use of LXR modulators for the prevention and treatment of skin aging | NR1H2, NR1H3, SREBF1 | RORC 112/4885NR1I2 44/4885NR1H2 1/4885 |
| US-20040018560-A1 | Crystallized LXR polypeptide in complex with a ligand and screening methods employing same | NR1H3, NR1H2, NCOA3 | RORC 117/4885NR1I2 11/4885NR1H2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.